Literature DB >> 22895032

Molecular epidemiology of Acinetobacter baumannii bloodstream isolates obtained in the United States from 1995 to 2004 using rep-PCR and multilocus sequence typing.

Paul G Higgins1, Katharina Janssen, Maximilian M Fresen, Hilmar Wisplinghoff, Harald Seifert.   

Abstract

Using a repetitive-sequence-based (rep)-PCR (DiversiLab), we have molecularly typed Acinetobacter nosocomial bloodstream isolates (Acinetobacter baumannii [n = 187], Acinetobacter pittii [n = 23], and Acinetobacter nosocomialis [n = 61]) obtained from patients hospitalized in U.S. hospitals over a 10-year period (1995-2004) during a nationwide surveillance study (Surveillance and Control of Pathogens of Epidemiological Importance [SCOPE]). Patterns of A. baumannii rep-PCR were compared to those of previously identified international clonal lineages (ICs) and were further investigated by multilocus sequence typing (MLST) to compare the two typing methods. Forty-seven of the A. baumannii isolates clustered with the previously defined IC 2. ICs 1, 3, 6, and 7 were also detected. The remaining 81 isolates were unrelated to the described ICs. In contrast, A. pittii and A. nosocomialis isolates were more heterogeneous, as determined by rep-PCR. Our MLST results were in good correlation with the rep-PCR clusters. Our study confirms previous data indicating the predominance of a few major clonal A. baumannii lineages in the United States, particularly IC 2. The presence in the United States of A. baumannii ICs 1, 2, and 3 from as early as 1995 suggests that global dissemination of these lineages was an early event.

Entities:  

Mesh:

Year:  2012        PMID: 22895032      PMCID: PMC3486219          DOI: 10.1128/JCM.01759-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay.

Authors: 
Journal:  Infect Control Hosp Epidemiol       Date:  2002-02       Impact factor: 3.254

2.  Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK.

Authors:  Richard P Spence; Kevin J Towner; Caroline J Henwood; Dorothy James; Neil Woodford; David M Livermore
Journal:  J Med Microbiol       Date:  2002-12       Impact factor: 2.472

3.  Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals.

Authors:  Helke van Dessel; Lenie Dijkshoorn; Tanny van der Reijden; Nancy Bakker; Armand Paauw; Peterhans van den Broek; Jan Verhoef; Sylvain Brisse
Journal:  Res Microbiol       Date:  2004-03       Impact factor: 3.992

4.  Carbapenem-non-susceptible Acinetobacter baumannii of sequence type 92 or its single-locus variants with a G428T substitution in zone 2 of the rpoB gene.

Authors:  Yangsoon Lee; Jinhwa Lee; Seok Hoon Jeong; Jonghan Lee; Il Kwon Bae; Kyungwon Lee
Journal:  J Antimicrob Chemother       Date:  2010-11-03       Impact factor: 5.790

5.  Surveillance of nosocomial cross-infections due to three Acinetobacter genospecies (Acinetobacter baumannii, genospecies 3 and genospecies 13) during a 10-Year Observation period: serotyping, macrorestriction analysis of Genomic DNA and antibiotic susceptibilities.

Authors:  W H Traub; D Bauer
Journal:  Chemotherapy       Date:  2000 Jul-Aug       Impact factor: 2.544

6.  Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States.

Authors:  Hilmar Wisplinghoff; Tobias Paulus; Marianne Lugenheim; Danuta Stefanik; Paul G Higgins; Michael B Edmond; Richard P Wenzel; Harald Seifert
Journal:  J Infect       Date:  2011-12-20       Impact factor: 6.072

7.  Typing of Campylobacter jejuni and Campylobacter coli isolated from live broilers and retail broiler meat by flaA-RFLP, MLST, PFGE and REP-PCR.

Authors:  Megan Behringer; William G Miller; Omar A Oyarzabal
Journal:  J Microbiol Methods       Date:  2010-12-02       Impact factor: 2.363

8.  A 63 kb genomic resistance island found in a multidrug-resistant Acinetobacter baumannii isolate of European clone I from 1977.

Authors:  Lenka Krizova; Alexandr Nemec
Journal:  J Antimicrob Chemother       Date:  2010-06-17       Impact factor: 5.790

9.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

10.  AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains.

Authors:  Stéphane Corvec; Nathalie Caroff; Eric Espaze; Cécile Giraudeau; Henri Drugeon; Alain Reynaud
Journal:  J Antimicrob Chemother       Date:  2003-09-01       Impact factor: 5.790

View more
  20 in total

1.  Epidemic diffusion of OXA-23-producing Acinetobacter baumannii isolates in Italy: results of the first cross-sectional countrywide survey.

Authors:  Luigi Principe; Aurora Piazza; Tommaso Giani; Silvia Bracco; Maria Sofia Caltagirone; Fabio Arena; Elisabetta Nucleo; Federica Tammaro; Gian Maria Rossolini; Laura Pagani; Francesco Luzzaro
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

2.  Utility of Whole-Genome Sequencing in Characterizing Acinetobacter Epidemiology and Analyzing Hospital Outbreaks.

Authors:  Margaret A Fitzpatrick; Egon A Ozer; Alan R Hauser
Journal:  J Clin Microbiol       Date:  2015-12-23       Impact factor: 5.948

Review 3.  Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.

Authors:  Ming-Feng Lin; Chung-Yu Lan
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

4.  Typing of nosocomial outbreaks of Acinetobacter baumannii by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Antonella Mencacci; Claudia Monari; Christian Leli; Luca Merlini; Elena De Carolis; Antonietta Vella; Maria Cacioni; Sara Buzi; Emanuela Nardelli; Francesco Bistoni; Maurizio Sanguinetti; Anna Vecchiarelli
Journal:  J Clin Microbiol       Date:  2012-11-21       Impact factor: 5.948

5.  Molecular epidemiology of integron-associated antimicrobial gene cassettes in the clinical isolates of Acinetobacter baumannii from northern Taiwan.

Authors:  Ming-Feng Lin; Ming-Li Liou; Chi-Chao Tu; Hui-Wen Yeh; Chung-Yu Lan
Journal:  Ann Lab Med       Date:  2013-06-24       Impact factor: 3.464

6.  Epidemiological characterizations of class 1 integrons from multidrug-resistant acinetobacter isolates in Daejeon, Korea.

Authors:  Ji Youn Sung; Sun Hoe Koo; Semi Kim; Kye Chul Kwon
Journal:  Ann Lab Med       Date:  2014-06-19       Impact factor: 3.464

7.  Molecular analysis of Acinetobacter baumannii strains isolated in Lebanon using four different typing methods.

Authors:  Rayane Rafei; Fouad Dabboussi; Monzer Hamze; Matthieu Eveillard; Carole Lemarié; Marie-Pierre Gaultier; Hassan Mallat; Rima Moghnieh; Rola Husni-Samaha; Marie-Laure Joly-Guillou; Marie Kempf
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

8.  An outbreak of blaOXA-51-like- and blaOXA-66-positive Acinetobacter baumannii ST208 in the emergency intensive care unit.

Authors:  Satomi Asai; Kazuo Umezawa; Hideo Iwashita; Toshio Ohshima; Maya Ohashi; Mika Sasaki; Hideki Hayashi; Mari Matsui; Keigo Shibayama; Sadaki Inokuchi; Hayato Miyachi
Journal:  J Med Microbiol       Date:  2014-08-20       Impact factor: 2.472

9.  "Stormy waters ahead": global emergence of carbapenemases.

Authors:  Gopi Patel; Robert A Bonomo
Journal:  Front Microbiol       Date:  2013-03-14       Impact factor: 5.640

10.  Rapid molecular characterization of Acinetobacter baumannii clones with rep-PCR and evaluation of carbapenemase genes by new multiplex PCR in Hospital District of Helsinki and Uusimaa.

Authors:  Tanja Pasanen; Suvi Koskela; Sointu Mero; Eveliina Tarkka; Päivi Tissari; Martti Vaara; Juha Kirveskari
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.